HALO · Halozyme Therapeutics, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026TL;DR. Halozyme reported record Q2 2026 results with total revenue up 48% to $481 million and royalty revenue up 50% to $308 million, and raised full-year 2026 guidance across revenue, EBITDA, and EPS, driven by five new ENHANZE and Hypercon collaboration agreements signed year-to-date.
- + Royalty revenue grew 50% year-over-year to $308 million in Q2 2026, driven by recently launched products including a 143% increase in Vyvgart Hytrulo royalties to $72.6 million.
- + Signed five new ENHANZE and Hypercon collaboration agreements year-to-date (with GSK, Incyte, undisclosed nucleic acid partner, Vertex, and Oruka), exceeding the full-year goal of three.
- + Repurchased $332.8 million of shares in Q2 2026 at an average price of $69.30, completing the February 2024 program and executing against the new $1.0 billion program announced in May 2026.
- − Operating expenses rose sharply year-over-year, with R&D up to $27.7 million (from $17.5 million), SG&A up to $57.0 million (from $41.6 million), and amortization of intangibles up to $29.5 million (from $17.8 million), driven by recent acquisitions and litigation costs.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $328.8M | second quarter 2026 | — |
| EBITDA | $321.88M | Three Months Ended June 30, 2026 | — |
| Non-GAAP Diluted EPS non-GAAP | $2.28 | Three Months Ended June 30, 2026 | — |
| Non-GAAP Diluted Shares non-GAAP | 119.72M | Three Months Ended June 30, 2026 | — |
| Non-GAAP Net Income non-GAAP | $272.64M | Three Months Ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HALO
this stock
Halozyme Therapeutics, Inc.
|
$12.93B | +65.8% | -52.0% | 33.3 | 13.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +16.2% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -2.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +589.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HALO | -3.1% | +4.8% | +70.5% | +4.8% | +65.8% |
| SPY | -1.2% | -0.4% | +13.1% | -0.4% | +12.1% |
| vs SPY | -1.9% | +5.1% | +57.5% | +5.1% | +53.7% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.